Allure Of Apellis Enhanced By Stellar Launch Of Syfovre
First GA Treatment Off To Strong Start
Rival Iveric may be in the process of being bought by Astellas but that has done nothing to dampen interest in Apellis and its geographic atrophy treatment Syfovre which was only launched in March yet reached Q1 sales of over $18m.
You may also be interested in...
On the heels of Apellis's wildly successful launch for the geographic atrophy drug Syfovre, the company's co-founder and CEO spoke with In Vivo about what it takes to go from a start-up to a commercial-stage company and about the importance of honesty in leadership.
The fortunes of the foundation that controls Novo Nordisk and backs a wide range of scientific, humanitarian and social causes are set to be transformed by the spectacular commercial success of the weight loss blockbuster Wegovy.
With positive results from a Phase II proof of concept controlled human infection model study evaluating Neumifil under its belt, the Scottish biotech is preparing to put the drug through its paces in a chronic obstructive pulmonary disease trial next year.